Overview
Global Biological Skin Substitutes market reached US$ YY million in 2023 and is expected to reach US$ YY million by 2031, growing at a CAGR of YY% during the forecast period 2024-2031.
Biological Skin Substitutes replace the functions of skin which are classified further into temporary substitutes or permanent ones. A biological skin substitute should possess a few factors that make it ideal for use which are hydrophilicity, antibacterial activity, and good compatibility.
These are often used for surgical wounds, venous ulcers, diabetic foot ulcers and pressure ulcers. The biological skin grafts effectively boost healing and lower the symptoms of the wounds in a few days.
Market Dynamics: Drivers & Restraints
Increasing chronic wound cases
Chronic wounds occur due to severe burns, diabetes, trauma, and other dermatological conditions like vitiligo. However, the most common types are diabetic foot ulcers, pressure ulcers, and venous leg ulcers. For instance, according to Springer Nature Journal, 2023, approximately 15–25% of patients with diabetes have a high chance of developing diabetic foot ulcers during their lifetime. The annual incidence of diabetic foot ulcers in the world is around 9.1 to nearly 26.1 million.
According to the Royal College of Physicians Clinical Medicine Journal, 2023, the worldwide prevalence of diabetic foot ulcers is 6.3% which is on the rise due to the increasing incidence of diabetes among the geriatric population. Furthermore, according to Bio tissue, there are 6.5 million people in the U.S. who suffer from deficient chronic wound healing. The number rises with the increasing geriatric population in the US region.
Limited use
The use of biological skin substitutes is still limited as it comes with its disadvantages such as high cost and fragility. Revascularization and healing take a lot of time in a few patients and elasticity is very limited in cultured epithelial sheet grafts. Few instances, rejection of the graft is possible which makes the skin hard to heal in patients with severe injuries or third-degree burns. Amnion-derived skin substitutes are much higher in cost and less economical for middle-income patients.

Segment Analysis
The global biological skin substitutes market is segmented based on product type, application, end-user and region.
Temporary skin substitutes is Expected to Dominate the Market
Temporary skin substitutes hold the largest share in the segment due to the efficiency of wound healing. The use of temporary skin substitutes is increasing due to the lesser disadvantages than the permanent ones. Owing to the approvals and partnerships, the temporary skin substitutes is expected to drive the market.
For instance, in August 2022, Organogenesis, a regenerative medicine company recieved US Food and Drug Administration clearance for PuraPly MZ. It contains purified micronized porcine collagen that has been shown help support wound healing environment.
In January 2023, Mimedx Group, Inc. partnered with Gunze Medical to introduce EPIFIX, a placental tissue allograft in the Japanese market. It acts as a protective barrier for better wound healing.

Geographical Analysis
North America is Expected to Dominate the Global Market
North America is expected to hold the largest share in the segment due to the high prevalence of diabetes and diabetes-associated ulcers among the people in this region. For instance, according to the National Institute of Health, 2023, more than 1.6 million people in the United States suffer from diabetic foot ulcers. Increasing diabetes cases are seen in America due to unhealthy eating habits and sedentary lifestyles.
Furthermore, according to the Canadian Diabetes Association, 2023, more than 30% live with diabetes or prediabetes. Hence, in June 2023, the Federal Government approximately $1 million over three years to allow Diabetes Canada to begin the work of implementing strategies to treat diabetes in Canada.
Market Segmentation
By Product Type

  • Temporary Skin substitutes
    o Amnion
    o Cadaveric skin
    o Porcine skin
    o Others
  • Permanent Skin Substitutes


o Epicel
o Alloderm
o Integra
o Others
By Application

  • Burns
  • Cancer
  • Injuries
  • Dermatologic conditions
  • Others
    By End User
  • Hospitals
  • Dermatology Clinics
  • Ambulatory Surgical Centers
  • Others
    By Region
  • North America
    o U.S.
    o Canada
    o Mexico
  • Europe


o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe

  • South America
    o Brazil
    o Argentina
    o Rest of South America
  • Asia-Pacific


o China
o India
o Japan
o Australia
o Rest of Asia-Pacific

  • Middle East and Africa
    Key Developments
  • In January 2023, the Southeastern Wound Healing Center, run by Healogics LLC launched a campaign named COME HEAL. The campaign is aimed at spreading awareness about sophisticated medical care for complex wounds.

    Competitive Landscape
    The major global players in the biological skin substitutes market include Vericel Corporation, Organogenesis Inc, Biotissue, Integra Lifesciences, Tissue Regenix Group, Smith & Nephew plc, ConvaTec, Stryker Corporation, Mimedx Group, Inc among others.
    Why Purchase the Report?
  • To visualize the global biological skin substitutes market segmentation based on product type, application, end user and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of biological skin substitutes market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.
    The global biological skin substitutes disease market report would provide approximately 55 tables, 57 figures and 186 pages.
    Target Audience 2023
  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies